DE60135904D1 - Arzneien zur behandlung von nervenerkrankungen - Google Patents

Arzneien zur behandlung von nervenerkrankungen

Info

Publication number
DE60135904D1
DE60135904D1 DE60135904T DE60135904T DE60135904D1 DE 60135904 D1 DE60135904 D1 DE 60135904D1 DE 60135904 T DE60135904 T DE 60135904T DE 60135904 T DE60135904 T DE 60135904T DE 60135904 D1 DE60135904 D1 DE 60135904D1
Authority
DE
Germany
Prior art keywords
growth factor
nerve growth
factor production
enhancing
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60135904T
Other languages
English (en)
Inventor
Hiromu Ohnogi
Masahiro Shiraga
Eiji Kobayashi
Tuo-Ping Li
Suzu Deguchi
Eiji Nishiyama
Hiroaki Sagawa
Ikunoshin Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of DE60135904D1 publication Critical patent/DE60135904D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60135904T 2000-01-27 2001-01-26 Arzneien zur behandlung von nervenerkrankungen Expired - Fee Related DE60135904D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000019208 2000-01-27
JP2000019331 2000-01-27
JP2000254683 2000-08-24
JP2000308519 2000-10-06
PCT/JP2001/000513 WO2001054682A1 (fr) 2000-01-27 2001-01-26 Medicaments

Publications (1)

Publication Number Publication Date
DE60135904D1 true DE60135904D1 (de) 2008-11-06

Family

ID=27480961

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135904T Expired - Fee Related DE60135904D1 (de) 2000-01-27 2001-01-26 Arzneien zur behandlung von nervenerkrankungen

Country Status (10)

Country Link
US (1) US7268160B2 (de)
EP (1) EP1254658B1 (de)
JP (1) JP4249926B2 (de)
KR (2) KR100711537B1 (de)
CN (1) CN100346776C (de)
AT (1) ATE409028T1 (de)
AU (1) AU2001228825A1 (de)
DE (1) DE60135904D1 (de)
TW (1) TWI255181B (de)
WO (1) WO2001054682A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127572A3 (de) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Verwendung von Flavonen zur Behandlung von Cyclooxygenase-2 ermittelten Krankheiten
KR20020089440A (ko) * 2000-04-11 2002-11-29 다카라 바이오 가부시키가이샤 치료제
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
EP1574506A4 (de) 2002-10-01 2007-05-30 Takara Bio Inc Heilmittel
AU2003277630A1 (en) * 2002-11-12 2004-06-03 Takara Bio Inc. Agent for improving learning and memorizing abilities
US20070092551A1 (en) * 2003-05-02 2007-04-26 Takara Bio Inc. Therapeutic agent
KR20060121273A (ko) * 2003-12-05 2006-11-28 다카라 바이오 가부시키가이샤 치료제
JPWO2005074906A1 (ja) * 2004-02-06 2008-01-10 タカラバイオ株式会社 治療剤
EP1883453A1 (de) * 2005-05-26 2008-02-06 Council Of Scientific And Industrial Research Pharmazeutische zusammensetzung mit eignung bei der behandlung von hepatozellulärem karzinom
JP2007230946A (ja) * 2006-03-02 2007-09-13 Nagase & Co Ltd 神経突起伸長剤
JP4912708B2 (ja) * 2006-03-24 2012-04-11 三井農林株式会社 新規物質ｔｍｒ
WO2009013168A1 (en) * 2007-07-25 2009-01-29 Symrise Gmbh & Co. Kg 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanone and its use as antioxidant
CN102697757B (zh) * 2012-05-18 2014-06-04 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用
JP2017043572A (ja) * 2015-08-28 2017-03-02 株式会社ファンケル ヘリピロンａを有効成分とするｂｄｎｆ産生促進剤
CN109651121B (zh) * 2019-01-25 2021-11-26 陕西理工大学 一种Robtein的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA945175A (en) * 1970-11-16 1974-04-09 Bunzo Nomiya Benzalacetone or acetophenone amidinohydrazone derivatives and the production thereof
FI874163A (fi) 1986-09-26 1988-03-27 Mitsui Toatsu Chemicals Katekolderivat samt preparat innehaollande desamma foer haemmande och botande av regressiva sjukdomar i det centrala nervsystemet.
JPS6442422A (en) 1987-08-10 1989-02-14 Tsumura & Co Antiulcer agent
KR890700117A (ko) 1986-12-12 1989-03-02 쓰무라 아끼라 유효성분으로서 칼콘 유도체를 함유하는 항 궤양제 및 신규의 칼콘 유도체
US5234951A (en) 1986-12-12 1993-08-10 Tsumura Juntendo, Inc. Anti-ulcer agent comprising chalcone derivative
JPH01125320A (ja) 1987-11-09 1989-05-17 Tsumura & Co テストステロン−５α−リダクターゼ阻害剤
JPH02104568A (ja) 1988-06-22 1990-04-17 Yoshitomi Pharmaceut Ind Ltd 神経成長因子産生促進作用剤
JPH02187765A (ja) 1989-01-14 1990-07-23 Oki Electric Ind Co Ltd コントラスト増強用の光脱色性層用材料およびそれを用いたパターン形成方法
JPH08768B2 (ja) * 1989-08-24 1996-01-10 武田薬品工業株式会社 神経成長因子分泌誘導剤
JPH03122645A (ja) 1989-10-05 1991-05-24 Nippon Kanko Shikiso Kenkyusho:Kk ホトレジスト用光吸収材料
JP2719042B2 (ja) 1990-11-22 1998-02-25 三共株式会社 神経成長因子産生分泌促進剤
JPH07110812B2 (ja) 1990-12-11 1995-11-29 財団法人喫煙科学研究財団 神経成長因子生合成促進剤
JPH0578384A (ja) 1991-03-27 1993-03-30 Taisho Pharmaceut Co Ltd フラボノール誘導体
JPH0561220A (ja) 1991-08-30 1993-03-12 Ricoh Co Ltd 電子写真感光体
JPH05246932A (ja) * 1992-03-04 1993-09-24 Nippon High Potsukusu:Kk ３，４−ジヒドロキシカルコン誘導体
JPH07194355A (ja) * 1993-12-28 1995-08-01 Sanei Gen F F I Inc エタノール製剤
JPH07285856A (ja) * 1994-04-21 1995-10-31 Hoechst Japan Ltd 骨粗鬆症治療剤
JPH0827086A (ja) 1994-07-22 1996-01-30 Sagami Chem Res Center Ｎ−アシル−ｎ−置換シンナモイルエチレンジアミン誘導体
FR2747568B1 (fr) 1996-04-17 1999-09-17 Oreal Utilisation d'au moins un inhibiteur de lipoxygenase et d'au moins un inhibiteur de cyclo-oxygenase pour modifier la pousse des poils et/ou des cheveux
JPH10114649A (ja) * 1996-10-15 1998-05-06 Dokutaazu Kosumeteikusu:Kk 津液改善剤及びそれを含有する経口投与用組成物
GB9712966D0 (en) 1997-06-19 1997-08-27 Indena Spa Novel chalcones
JPH11246398A (ja) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd 生体内過酸化脂質増加に起因する疾患の予防または治療剤
EP0998939A1 (de) * 1998-09-09 2000-05-10 The School Of Pharmacy, University Of London Chalcone Pflanzenextrakten zur Anwendung in der Therapie
JP4171178B2 (ja) 1999-02-19 2008-10-22 タカラバイオ株式会社 治療剤
AU3837300A (en) * 1999-04-15 2000-11-02 Takara Shuzo Co., Ltd. Remedies
WO2001030335A2 (en) * 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease

Also Published As

Publication number Publication date
AU2001228825A1 (en) 2001-08-07
EP1254658A1 (de) 2002-11-06
WO2001054682A1 (fr) 2001-08-02
CN1419448A (zh) 2003-05-21
EP1254658B1 (de) 2008-09-24
JP4249926B2 (ja) 2009-04-08
KR20060095786A (ko) 2006-09-01
KR20020073186A (ko) 2002-09-19
ATE409028T1 (de) 2008-10-15
TWI255181B (en) 2006-05-21
CN100346776C (zh) 2007-11-07
US20030144316A1 (en) 2003-07-31
US7268160B2 (en) 2007-09-11
EP1254658A4 (de) 2003-06-18
KR100711537B1 (ko) 2007-04-27

Similar Documents

Publication Publication Date Title
DE60135904D1 (de) Arzneien zur behandlung von nervenerkrankungen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE405564T1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
EP1302542A4 (de) Neues, physiologisch aktives peptid und dessen verwendung
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
HUP0105027A2 (hu) N-Heterociklusos vegyületek karbonsavszármazékai és karbonsav-izoszterei és alkalmazásuk
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
DE60126829D1 (de) Kombination von drei Substanzen zur Vorbeugung und Behandlung von Arthritis
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
AU2001266289A1 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
DE69521536D1 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
ATE265851T1 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE68916651D1 (de) Heilmittel zur behandlung von toxoplasmose.
HUP0105412A2 (hu) 3-Izoxazolidinon- és karboxi-alkil-hidroxámsav-származékok alkalmazása fertőzések kezelésére szolgáló gyógyszerkészítmények előállítására
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee